↓ Skip to main content

Dove Medical Press

Article Metrics

Nanomedicine applications in the treatment of breast cancer: current state of the art

Overview of attention for article published in International Journal of Nanomedicine, August 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
45 Dimensions

Readers on

mendeley
112 Mendeley
Title
Nanomedicine applications in the treatment of breast cancer: current state of the art
Published in
International Journal of Nanomedicine, August 2017
DOI 10.2147/ijn.s123437
Pubmed ID
Authors

Di Wu, Mengjie Si, Hui-Yi Xue, Ho Lun Wong

Abstract

Breast cancer is the most common malignant disease in women worldwide, but the current drug therapy is far from optimal as indicated by the high death rate of breast cancer patients. Nanomedicine is a promising alternative for breast cancer treatment. Nanomedicine products such as Doxil(®) and Abraxane(®) have already been extensively used for breast cancer adjuvant therapy with favorable clinical outcomes. However, these products were originally designed for generic anticancer purpose and not specifically for breast cancer treatment. With better understanding of the molecular biology of breast cancer, a number of novel promising nanotherapeutic strategies and devices have been developed in recent years. In this review, we will first give an overview of the current breast cancer treatment and the updated status of nanomedicine use in clinical setting, then discuss the latest important trends in designing breast cancer nanomedicine, including passive and active cancer cell targeting, breast cancer stem cell targeting, tumor microenvironment-based nanotherapy and combination nanotherapy of drug-resistant breast cancer. Researchers may get insight from these strategies to design and develop nanomedicine that is more tailored for breast cancer to achieve further improvements in cancer specificity, antitumorigenic effect, antimetastasis effect and drug resistance reversal effect.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 112 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 112 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 22 20%
Student > Master 22 20%
Student > Bachelor 16 14%
Researcher 8 7%
Other 4 4%
Other 13 12%
Unknown 27 24%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 25 22%
Biochemistry, Genetics and Molecular Biology 22 20%
Chemistry 11 10%
Medicine and Dentistry 8 7%
Engineering 5 4%
Other 9 8%
Unknown 32 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 September 2017.
All research outputs
#8,470,309
of 14,638,868 outputs
Outputs from International Journal of Nanomedicine
#994
of 2,819 outputs
Outputs of similar age
#111,076
of 223,292 outputs
Outputs of similar age from International Journal of Nanomedicine
#18
of 55 outputs
Altmetric has tracked 14,638,868 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,819 research outputs from this source. They receive a mean Attention Score of 3.2. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 223,292 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 55 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.